[{"address1": "930 Winter Street", "address2": "Suite M-500", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "617 443 2400", "website": "https://aerovatetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 51, "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 1.46, "open": 1.6, "dayLow": 1.51, "dayHigh": 1.7, "regularMarketPreviousClose": 1.46, "regularMarketOpen": 1.6, "regularMarketDayLow": 1.51, "regularMarketDayHigh": 1.7, "beta": 1.296, "forwardPE": -1.0331125, "volume": 5603060, "regularMarketVolume": 5603060, "averageVolume": 864740, "averageVolume10days": 4266310, "averageDailyVolume10Day": 4266310, "bid": 1.2, "ask": 1.94, "bidSize": 200, "askSize": 200, "marketCap": 44962788, "fiftyTwoWeekLow": 1.25, "fiftyTwoWeekHigh": 32.415, "fiftyDayAverage": 19.2196, "twoHundredDayAverage": 18.393076, "currency": "USD", "enterpriseValue": -53619000, "floatShares": 10157819, "sharesOutstanding": 28822300, "sharesShort": 2193015, "sharesShortPriorMonth": 1251584, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0761, "heldPercentInsiders": 0.00034000003, "heldPercentInstitutions": 1.07618, "shortRatio": 14.37, "shortPercentOfFloat": 0.19459999, "impliedSharesOutstanding": 28822300, "bookValue": 3.258, "priceToBook": 0.47882137, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -82187000, "trailingEps": -3.03, "forwardEps": -1.51, "enterpriseToEbitda": 0.607, "52WeekChange": -0.90608066, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "AVTE", "underlyingSymbol": "AVTE", "shortName": "Aerovate Therapeutics, Inc.", "longName": "Aerovate Therapeutics, Inc.", "firstTradeDateEpochUtc": 1625059800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "cbf275de-3fc7-3baa-b402-2df34de7643f", "messageBoardId": "finmb_650355034", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.56, "targetHighPrice": 3.0, "targetLowPrice": 2.0, "targetMeanPrice": 2.25, "targetMedianPrice": 2.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 4, "totalCash": 99334000, "totalCashPerShare": 3.448, "ebitda": -88285000, "totalDebt": 774000, "quickRatio": 6.401, "currentRatio": 6.653, "debtToEquity": 0.851, "returnOnAssets": -0.47785, "returnOnEquity": -0.80575997, "freeCashflow": -38999500, "operatingCashflow": -69027000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]